Toxicologic aspects of heroin substitution treatment

被引:19
作者
Cone, EJ
Preston, KL
机构
[1] NIDA, Intramural Res Program, Baltimore, MD 21224 USA
[2] ConeChem Res, Baltimore, MD USA
关键词
heroin; methadone; levomethadyl acetate; urinalysis;
D O I
10.1097/00007691-200204000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Heroin abuse is an international problem with which all countries must continually cope. Many countries have implemented heroin substitution therapy as an effective means of decreasing illicit heroin use, crime, HIV risk, and death, and in improving employment and social adjustment. Although methadone is the most commonly used medication for heroin substitution, other agonists in current use include levomethadyl acetate (LAAM), buprenorphine, and pharmaceutical-grade heroin. This report reviews toxicologic issues that arise in these programs. A broad array of testing methodologies are available that allow selection of on-site testing or laboratory-based methodology. Urine specimens may be monitored for nonprescribed drugs on a qualitative or semiquantitative basis. Methods for differentiating opiate sources by urinalysis have been proposed to distinguish poppy seed consumption from heroin abuse and for distinguishing pharmaceutical-grade heroin from illicit heroin. Therapeutic drug monitoring for methadone in plasma continues to be evaluated for use in establishing adequate dosing and detecting diversion, and new methods have been devised for measurement of the optical isomers of methadone in plasma. Biologic specimens, in addition to plasma and urine, have been evaluated for use in drug monitoring, including sweat, hair, and oral fluid, with promising results. Overall, the many recent developments in testing methodology provide more effective means to assess patients in heroin substitution programs and should contribute to improvements in public health.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 45 条
[1]   REDUCING THE RISK OF AIDS THROUGH METHADONE-MAINTENANCE TREATMENT [J].
BALL, JC ;
LANGE, WR ;
MYERS, CP ;
FRIEDMAN, SR .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1988, 29 (03) :214-226
[2]  
BARTHWELL A, 1989, ARCH GEN PSYCHIAT, V46, P957
[3]   Methadone maintenance and drug-related crime [J].
Bell, J ;
Mattick, R ;
Hay, A ;
Chan, J ;
Hall, W .
JOURNAL OF SUBSTANCE ABUSE, 1997, 9 :15-25
[4]   Saliva/plasma ratio of methadone and EDDP [J].
Bermejo, AM ;
Lucas, ACS ;
Tabernero, MJ .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2000, 24 (01) :70-72
[5]   A CLINICAL-TRIAL OF BUPRENORPHINE - COMPARISON WITH METHADONE IN THE DETOXIFICATION OF HEROIN-ADDICTS [J].
BICKEL, WK ;
STITZER, ML ;
BIGELOW, GE ;
LIEBSON, IA ;
JASINSKI, DR ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (01) :72-78
[6]  
BICKEL WK, 1988, J PHARMACOL EXP THER, V247, P47
[7]   RETENTION IN METHADONE-MAINTENANCE AND HEROIN-ADDICTS RISK OF DEATH [J].
CAPLEHORN, JRM ;
DALTON, MSYN ;
CLUFF, MC ;
PETRENAS, AM .
ADDICTION, 1994, 89 (02) :203-209
[8]   NARCOTIC BLOCKADE [J].
DOLE, VP ;
NYSWANDER, ME ;
KREEK, MJ .
ARCHIVES OF INTERNAL MEDICINE, 1966, 118 (04) :304-+
[9]   Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics [J].
Eap, CB ;
Finkbeiner, T ;
Gastpar, M ;
Scherbaum, N ;
Powell, K ;
Baumann, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (05) :385-389
[10]  
ELSOHLY MA, 1998, FORENSIC SCI REV, V1, P14